» Articles » PMID: 30538511

Treatment of Candidemia in a Nationwide Setting: Increased Survival with Primary Echinocandin Treatment

Abstract

Background: In accordance with international guidelines, primary antifungal treatment (AFT) of candidemia with echinocandins has been nationally recommended in Denmark since 2009. Our nationwide cohort study describes the management of candidemia treatment focusing on the impact of prophylactic AFT on species distribution, the rate of adherence to the recommended national guidelines for AFT, and the effect of AFT on patient outcomes.

Materials And Methods: Incident candidemia cases from a 2-year period, 2010-2011, were included. Information on AFT was retrospectively collected from patient charts. Vital status was obtained from the Danish Civil Registration System. HRs of mortality were reported with 95% CIs using Cox regression.

Results: A total of 841 candidemia patients was identified. Prior to candidemia diagnosis, 19.3% of patients received AFT (162/841). The risk of non- candidemia increased after prior AFT (59.3% vs 45.5% among nontreated). Echinocandins as primary AFT were given for 44.2% (302/683) of patients. Primary treatment with echinocandins resulted in adequate treatment in a higher proportion of patients (97.7% vs 72.1%) and was associated with lower 0- to 14-day mortality compared with azole treatment (adj. HR 0.76, 95% CI: 0.55-1.06). Significantly lower 0- to 14-day mortality was observed for patients with and with echinocandin treatment compared with azole treatment (adj. HR 0.50, 95% CI: 0.28-0.89), but not for patients with or .

Conclusion: The association shown between prior AFT and non- species underlines the importance of treatment history when selecting treatment for candidemia. Compliance with national recommendations was low, but similar to previously reported international rates. Primary treatment of candidemia with echinocandins compared with azoles yielded both a higher proportion of adequately treated patients and improved mortality rates. This real-life setting supports guidelines recommendation, and further focus on compliance with these seems warranted.

Citing Articles

Pichia kudriavzevii (Candida krusei): A systematic review to inform the World Health Organisation priority list of fungal pathogens.

Nguyen T, Kim H, Stocker S, Kidd S, Alastruey-Izquierdo A, Dao A Med Mycol. 2024; 62(6).

PMID: 38935911 PMC: 11210618. DOI: 10.1093/mmy/myad132.


Candida parapsilosis complex in the clinical setting.

Govrins M, Lass-Florl C Nat Rev Microbiol. 2023; 22(1):46-59.

PMID: 37674021 DOI: 10.1038/s41579-023-00961-8.


Antifungal therapy in the management of fungal secondary infections in COVID-19 patients: A systematic review and meta-analysis.

Sah S, Shariff A, Pathakamuri N, Ramaswamy S, Ramesh M, Undela K PLoS One. 2022; 17(7):e0271795.

PMID: 35901069 PMC: 9333218. DOI: 10.1371/journal.pone.0271795.


Intensive Care Antifungal Stewardship Programme Based on T2Candida PCR and Mannan Antigen: A Prospective Study.

Helweg-Larsen J, Steensen M, Pedersen F, Bredahl Jensen P, Perch M, Moller K J Fungi (Basel). 2021; 7(12).

PMID: 34947026 PMC: 8705527. DOI: 10.3390/jof7121044.


Clinical and epidemiological aspects of Candidemia in eight medical centers in the state of Parana, Brazil: Parana Candidemia Network.

de Oliveira C, Colombo A, Francisco E, de Lima B, Gandra R, de Carvalho M Braz J Infect Dis. 2020; 25(1):101041.

PMID: 33370563 PMC: 9392142. DOI: 10.1016/j.bjid.2020.11.006.


References
1.
Leroy O, Bailly S, Gangneux J, Mira J, Devos P, Dupont H . Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study. Ann Intensive Care. 2016; 6(1):2. PMC: 4705061. DOI: 10.1186/s13613-015-0103-7. View

2.
Puig-Asensio M, Peman J, Zaragoza R, Garnacho-Montero J, Martin-Mazuelos E, Cuenca-Estrella M . Impact of therapeutic strategies on the prognosis of candidemia in the ICU. Crit Care Med. 2014; 42(6):1423-32. DOI: 10.1097/CCM.0000000000000221. View

3.
Cornely O, Bassetti M, Calandra T, Garbino J, Kullberg B, Lortholary O . ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012; 18 Suppl 7:19-37. DOI: 10.1111/1469-0691.12039. View

4.
Hirano R, Sakamoto Y, Kitazawa J, Yamamoto S, Kayaba H . Epidemiology, practice patterns, and prognostic factors for candidemia; and characteristics of fourteen patients with breakthrough bloodstream infections: a single tertiary hospital experience in Japan. Infect Drug Resist. 2018; 11:821-833. PMC: 5987783. DOI: 10.2147/IDR.S156633. View

5.
Rajendran R, Sherry L, Deshpande A, Johnson E, Hanson M, Williams C . A Prospective Surveillance Study of Candidaemia: Epidemiology, Risk Factors, Antifungal Treatment and Outcome in Hospitalized Patients. Front Microbiol. 2016; 7:915. PMC: 4910670. DOI: 10.3389/fmicb.2016.00915. View